Genentech's Tecentriq meets PFS endpoint in first-line NSCLC

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) said Tecentriq atezolizumab (MPDL3280A, RG7446) met the co-primary endpoint of improving progression-free survival (PFS) in the Phase III IMpower150 trial as first-line treatment of advanced stage IV non-squamous non-small cell lung cancer (NSCLC). The endpoint compared Tecentriq plus Avastin bevacizumab and chemotherapy vs. Avastin and chemotherapy alone.

Tecentriq is already approved in the U.S. to treat metastatic NSCLC in patients who have progressed during or following platinum-containing chemotherapy. Genentech said it plans to submit the data to regulatory agencies worldwide, including FDA and EMA...